Articles

Guest Commentary: Should you be concerned about temporary data?

As regulatory agencies evolve their thinking around data integrity mandates, the guidance is pointing to curbing the ability to alter data in temporary memory before it becomes permanent
Written byJeff Vannest
Brought to you byLabVantage
| 3 min read

If someone says data integrity isn’t a new issue, they might not be paying attention to the matter of temporary data. While it’s been two years since the World Health Organization announced its good data and record management practices, and only a year since the U.S. Food and Drug Administration (FDA) and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) issued draft guidance to improve data integrity, one aspect is gaining attention: that of temporary memory. While these regulatory agencies evolve their thinking around data integrity mandates, the guidance is pointing to curbing the ability to alter data in temporary memory before it becomes permanent.

The issue of temporary data

Because data is central to a regulator’s mission to ensure the safety, efficacy and quality of pharmaceuticals, regulatory agencies such as FDA and MHRA seek to ensure that data submitted to them has not been falsified, omitted, hidden or substituted. This includes data points that have been entered, but perhaps never saved.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.